---
schema_version: "secwatch.filing_event.v1"
accession: "0000920148-23-000012"
form_type: "8-K"
ticker: "LH"
cik: "0000920148"
company_name: "LABCORP HOLDINGS INC."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T10:09:07.089890+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Labcorp reports Q4 2022 revenue $3.7B, GAAP EPS $0.86 (vs $5.75 YoY), provides FY2023 adjusted EPS guidance $16-$18

## Summary
- Q4 rev $3.67B (-9.4% YoY); GAAP diluted EPS $0.86 vs $5.75; adj EPS $4.14 vs $6.77.
- Full-year 2022 rev $14.88B (-7.7%); adj EPS $19.94 vs $28.52; free cash flow $1.47B.
- Diagnostics base business organic +6.4%; Drug Development backlog $16.3B (+8.9%), net book-to-bill 1.27.
- FY2023 guidance: total rev growth 1-4%, base business 8.5-10.5%; adj EPS $16-$18; FCF $1.0-$1.2B.
- Spin-off of Clinical Development (Fortrea) on track for mid-2023; Board authorized additional $1B share buyback; $0.72 dividend payable Mar 13.

## SEC filing metadata
- accession: 0000920148-23-000012
- form_type: 8-K
- ticker: LH
- cik: 0000920148
- company_name: LABCORP HOLDINGS INC.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/920148/000092014823000012/0000920148-23-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/920148/000092014823000012/lh-20230216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000920148-23-000012
- JSON: https://secwatch.observer/filing/0000920148-23-000012.json
- Plain text: https://secwatch.observer/filing/0000920148-23-000012.txt

## Key facts
- Earnings Releases
  LABCORP HOLDINGS INC. updated its guidance (initiated).
  - Guidance: initiated
  - Result: guidance update
  source text: Full-Year 2023 Guidance: Adjusted EPS of $16.00 to $18.00 and Free Cash Flow of $1.0 billion to $1.2 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/920148/000092014823000012/0000920148-23-000012-index.htm
- Earnings Releases
  LABCORP HOLDINGS INC. reported the fourth quarter and year ended Dec. 31, 2022 results: revenue $14.88 billion, net income $1.28 billion, EPS $13.97.
  - Period: the fourth quarter and year ended Dec. 31, 2022
  - Revenue: $14.88 billion
  - Net income: $1.28 billion
  - EPS: $13.97
  - Result: reported results
  source text: for share repurchases, bringing the total available authorization to approximately $1.53 billion. 2 Consolidated Results Fourth Quarter Results Revenue for the quarter was $3.67 billion, a decrease of (9.4%) from $4.06 billion in the fourth quarter of 2021. The decrease was due to organic revenue of (9.4%) and foreign currency translation of (1.3%), partially
  evidence_url: https://www.sec.gov/Archives/edgar/data/920148/000092014823000012/0000920148-23-000012-index.htm
- Earnings Releases
  LABCORP HOLDINGS INC. reported the fourth quarter and year ended Dec. 31, 2022 results: revenue $14.88 billion, net income $1.28 billion, EPS $13.97.
  - Period: the fourth quarter and year ended Dec. 31, 2022
  - Revenue: $14.88 billion
  - Net income: $1.28 billion
  - EPS: $13.97
  - Result: reported results
  source text: Revenue was $14.88 billion, a decrease of (7.7%) from $16.12 billion in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/920148/000092014823000012/0000920148-23-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.